RE-Vana Therapeutics CEO Michael J. O’Rourke announces two new team appointments:

Following our successful $11.9M Series A in November 2022, Re-Vana Therapeutics is delighted to further strengthen our team with two new appointments as we develop our sustained release biologics platforms:

Patrick Ruane is appointed Chief Operating Officer

https://lnkd.in/g_pu-ftK

Raj Thakur will join on a 2 year sabbatical from Queens University Belfast as Chief Technology Officer

https://lnkd.in/gg8sWAyF

Congrats to both Patrick and Raj

New Re-Vana career opportunities in Program Management, Quality Control, Biologics Development and Technical Services will be announced over the coming weeks.

https://www.linkedin.com/posts/mjorourke_following-our-successful-119m-series-a-activity-7016825730953076736-c9Ly?utm_source=share&utm_medium=member_desktop